severe chronic plaque psoriasis
Rheumatology · 2021–2024
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ustekinumab Treatment of severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, moderate to severe ulcerative colitis,… | Mar 2024 | Recommended | input received Colitis Australia |
| secukinumab Requested amendment to increase maximum quantity from one to two injections and reduce repeats from five to two for the continuing treatment phase of… | Jul 2021 | Not recommended | none received |
Who spoke
Colitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.